Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 317

1.

Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.

Focken T, Burford K, Grimwood ME, Zenova A, Andrez JC, Gong W, Wilson M, Taron M, Decker S, Lofstrand V, Chowdhury S, Shuart N, Lin S, Goodchild SJ, Young C, Soriano M, Tari PK, Waldbrook M, Nelkenbrecher K, Kwan R, Lindgren A, de Boer G, Lee S, Sojo L, Devita RJ, Cohen CJ, Wesolowski SS, Johnson JP, Dehnhardt CM, Empfield JR.

J Med Chem. 2019 Sep 17. doi: 10.1021/acs.jmedchem.9b01032. [Epub ahead of print]

PMID:
31525968
2.

A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.

Hoogi S, Eisenberg V, Mayer S, Shamul A, Barliya T, Cohen CJ.

J Immunother Cancer. 2019 Sep 9;7(1):243. doi: 10.1186/s40425-019-0721-y.

3.

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.

Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, Eisenberg V, Wohlleber D, Steiger K, Merkler D, Delorenzi M, Knolle PA, Cohen CJ, Thimme R, Youngblood B, Zehn D.

Nature. 2019 Jul;571(7764):265-269. doi: 10.1038/s41586-019-1326-9. Epub 2019 Jun 17.

PMID:
31207605
4.

Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides.

Besser H, Yunger S, Merhavi-Shoham E, Cohen CJ, Louzoun Y.

J Immunother Cancer. 2019 May 22;7(1):135. doi: 10.1186/s40425-019-0595-z.

5.

Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain.

McKerrall SJ, Nguyen T, Lai KW, Bergeron P, Deng L, DiPasquale A, Chang JH, Chen J, Chernov-Rogan T, Hackos DH, Maher J, Ortwine DF, Pang J, Payandeh J, Proctor WR, Shields SD, Vogt J, Ji P, Liu W, Ballini E, Schumann L, Tarozzo G, Bankar G, Chowdhury S, Hasan A, Johnson JP Jr, Khakh K, Lin S, Cohen CJ, Dehnhardt CM, Safina BS, Sutherlin DP.

J Med Chem. 2019 Apr 25;62(8):4091-4109. doi: 10.1021/acs.jmedchem.9b00141. Epub 2019 Apr 16.

PMID:
30943032
6.

RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis-Novel Targets for Therapy?

Vecellio M, Cohen CJ, Roberts AR, Wordsworth PB, Kenna TJ.

Front Immunol. 2019 Jan 10;9:3132. doi: 10.3389/fimmu.2018.03132. eCollection 2018. Review.

7.

T-cells "à la CAR-T(e)" - Genetically engineering T-cell response against cancer.

Eisenberg V, Hoogi S, Shamul A, Barliya T, Cohen CJ.

Adv Drug Deliv Rev. 2019 Feb 15;141:23-40. doi: 10.1016/j.addr.2019.01.007. Epub 2019 Jan 14. Review.

PMID:
30653988
8.

Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (NaV) 1.7 with Potent Analgesic Activity.

Sun S, Jia Q, Zenova AY, Wilson MS, Chowdhury S, Focken T, Li J, Decker S, Grimwood ME, Andrez JC, Hemeon I, Sheng T, Chen CA, White A, Hackos DH, Deng L, Bankar G, Khakh K, Chang E, Kwan R, Lin S, Nelkenbrecher K, Sellers BD, DiPasquale AG, Chang J, Pang J, Sojo L, Lindgren A, Waldbrook M, Xie Z, Young C, Johnson JP, Robinette CL, Cohen CJ, Safina BS, Sutherlin DP, Ortwine DF, Dehnhardt CM.

J Med Chem. 2019 Jan 24;62(2):908-927. doi: 10.1021/acs.jmedchem.8b01621. Epub 2018 Dec 21.

PMID:
30499663
9.

Selective NaV1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain.

Bankar G, Goodchild SJ, Howard S, Nelkenbrecher K, Waldbrook M, Dourado M, Shuart NG, Lin S, Young C, Xie Z, Khakh K, Chang E, Sojo LE, Lindgren A, Chowdhury S, Decker S, Grimwood M, Andrez JC, Dehnhardt CM, Pang J, Chang JH, Safina BS, Sutherlin DP, Johnson JP Jr, Hackos DH, Robinette CL, Cohen CJ.

Cell Rep. 2018 Sep 18;24(12):3133-3145. doi: 10.1016/j.celrep.2018.08.063.

10.

Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaV1.7 Inhibitors for the Treatment of Pain.

Focken T, Chowdhury S, Zenova A, Grimwood ME, Chabot C, Sheng T, Hemeon I, Decker SM, Wilson M, Bichler P, Jia Q, Sun S, Young C, Lin S, Goodchild SJ, Shuart NG, Chang E, Xie Z, Li B, Khakh K, Bankar G, Waldbrook M, Kwan R, Nelkenbrecher K, Karimi Tari P, Chahal N, Sojo L, Robinette CL, White AD, Chen CA, Zhang Y, Pang J, Chang JH, Hackos DH, Johnson JP Jr, Cohen CJ, Ortwine DF, Sutherlin DP, Dehnhardt CM, Safina BS.

J Med Chem. 2018 Jun 14;61(11):4810-4831. doi: 10.1021/acs.jmedchem.7b01826. Epub 2018 May 23.

PMID:
29737846
11.

Quantifying the genetic risk for the development of axial spondyloarthropathy: could this become a diagnostic tool?

Wordsworth BP, Cohen CJ, Vecellio M.

Curr Opin Rheumatol. 2018 Jul;30(4):319-323. doi: 10.1097/BOR.0000000000000517. Review.

PMID:
29702496
12.

Increased RNA Editing May Provide a Source for Autoantigens in Systemic Lupus Erythematosus.

Roth SH, Danan-Gotthold M, Ben-Izhak M, Rechavi G, Cohen CJ, Louzoun Y, Levanon EY.

Cell Rep. 2018 Apr 3;23(1):50-57. doi: 10.1016/j.celrep.2018.03.036.

13.

Evidence for a second ankylosing spondylitis-associated RUNX3 regulatory polymorphism.

Vecellio M, Cortes A, Roberts AR, Ellis J, Cohen CJ, Knight JC, Brown MA, Bowness P, Wordsworth BP.

RMD Open. 2018 Feb 8;4(1):e000628. doi: 10.1136/rmdopen-2017-000628. eCollection 2018.

14.

Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look".

Schwartz M, Camacho-Vanegas O, Wood AM, Dashkoff M, Whitelock C, Harkins TT, Cohen CJ, Beddoe AM, Dottino P, Martignetti JA.

Int J Gynecol Cancer. 2018 Mar;28(3):479-485. doi: 10.1097/IGC.0000000000001190.

15.

Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors.

Chernov-Rogan T, Li T, Lu G, Verschoof H, Khakh K, Jones SW, Beresini MH, Liu C, Ortwine DF, McKerrall SJ, Hackos DH, Sutherlin D, Cohen CJ, Chen J.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E792-E801. doi: 10.1073/pnas.1713701115. Epub 2018 Jan 8.

16.

Integration of biological/pathophysiological contexts to help clarify genotype-phenotype mismatches in monogenetic diseases. Childhood epilepsies associated with SCN2A as a case study.

Winquist RJ, Cohen CJ.

Biochem Pharmacol. 2018 May;151:252-262. doi: 10.1016/j.bcp.2018.01.003. Epub 2018 Jan 4. Review.

PMID:
29307654
17.

Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.

Eisenberg V, Shamalov K, Meir S, Hoogi S, Sarkar R, Pinker S, Markel G, Porgador A, Cohen CJ.

Front Immunol. 2017 Sep 29;8:1212. doi: 10.3389/fimmu.2017.01212. eCollection 2017.

18.

Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy.

Meir R, Shamalov K, Sadan T, Motiei M, Yaari G, Cohen CJ, Popovtzer R.

ACS Nano. 2017 Nov 28;11(11):11127-11134. doi: 10.1021/acsnano.7b05299. Epub 2017 Oct 20.

PMID:
29028305
19.

Sodium channel NaV1.9 mutations associated with insensitivity to pain dampen neuronal excitability.

Huang J, Vanoye CG, Cutts A, Goldberg YP, Dib-Hajj SD, Cohen CJ, Waxman SG, George AL Jr.

J Clin Invest. 2017 Jun 30;127(7):2805-2814. doi: 10.1172/JCI92373. Epub 2017 May 22.

20.

The mutational status of p53 can influence its recognition by human T-cells.

Shamalov K, Levy SN, Horovitz-Fried M, Cohen CJ.

Oncoimmunology. 2017 Jan 31;6(4):e1285990. doi: 10.1080/2162402X.2017.1285990. eCollection 2017.

21.

A novel lncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity.

Gasri-Plotnitsky L, Ovadia A, Shamalov K, Nizri-Megnaji T, Meir S, Zurer I, Cohen CJ, Ginsberg D.

Oncotarget. 2017 Apr 4;8(14):23775-23786. doi: 10.18632/oncotarget.15864.

22.

Investigation of a possible extended risk haplotype in the IL23R region associated with ankylosing spondylitis.

Roberts AR, Vecellio M, Cortes A, Knight JC, Cohen CJ, Wordsworth BP.

Genes Immun. 2017 Mar;18(2):105-108. doi: 10.1038/gene.2017.5. Epub 2017 Apr 6.

23.

MHC-multimer guided isolation of neoepitopes specific T cells as a potent-personalized cancer treatment strategy.

Bareli R, Cohen CJ.

Oncoimmunology. 2016 Jun 27;5(7):e1159370. doi: 10.1080/2162402X.2016.1159370. eCollection 2016 Jul.

24.

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, Frankenburg S, Ron I, Isacson R, Grenader T, Steinberg H, Cohen CJ, Peretz T, Lotem M.

J Immunother. 2016 Oct;39(8):321-8. doi: 10.1097/CJI.0000000000000138.

PMID:
27564312
25.

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.

Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF.

Cancer Immunol Res. 2016 Aug;4(8):669-78. doi: 10.1158/2326-6066.CIR-15-0215. Epub 2016 Jun 16.

26.

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.

Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, Cohen CJ, Phillips A, Lundgren JD, Neaton JD; INSIGHT SMART/ESPRIT/SILCAAT Study Group.

PLoS One. 2016 May 12;11(5):e0155100. doi: 10.1371/journal.pone.0155100. eCollection 2016.

27.

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

Focken T, Liu S, Chahal N, Dauphinais M, Grimwood ME, Chowdhury S, Hemeon I, Bichler P, Bogucki D, Waldbrook M, Bankar G, Sojo LE, Young C, Lin S, Shuart N, Kwan R, Pang J, Chang JH, Safina BS, Sutherlin DP, Johnson JP Jr, Dehnhardt CM, Mansour TS, Oballa RM, Cohen CJ, Robinette CL.

ACS Med Chem Lett. 2016 Jan 19;7(3):277-82. doi: 10.1021/acsmedchemlett.5b00447. eCollection 2016 Mar 10.

28.

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, Cooper LJ, Rosenberg SA.

Mol Ther. 2016 Jun;24(6):1078-1089. doi: 10.1038/mt.2016.51. Epub 2016 Mar 5.

29.

An ankylosing spondylitis-associated genetic variant in the IL23R-IL12RB2 intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation.

Roberts AR, Vecellio M, Chen L, Ridley A, Cortes A, Knight JC, Bowness P, Cohen CJ, Wordsworth BP.

Ann Rheum Dis. 2016 Dec;75(12):2150-2156. doi: 10.1136/annrheumdis-2015-208640. Epub 2016 Feb 25.

30.

Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.

Sweet DE, Altice FL, Cohen CJ, Vandewalle B.

PLoS One. 2016 Jan 25;11(1):e0147821. doi: 10.1371/journal.pone.0147821. eCollection 2016.

31.

Engineering T-Cell Specificity Genetically to Generate Anti-melanoma Reactivity.

Weizman E, Cohen CJ.

Methods Mol Biol. 2016 Jan 20. [Epub ahead of print]

PMID:
26786881
32.

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S.

AIDS. 2016 Jan;30(2):251-9. doi: 10.1097/QAD.0000000000000911.

PMID:
26684822
33.

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist.

Ahuja S, Mukund S, Deng L, Khakh K, Chang E, Ho H, Shriver S, Young C, Lin S, Johnson JP Jr, Wu P, Li J, Coons M, Tam C, Brillantes B, Sampang H, Mortara K, Bowman KK, Clark KR, Estevez A, Xie Z, Verschoof H, Grimwood M, Dehnhardt C, Andrez JC, Focken T, Sutherlin DP, Safina BS, Starovasnik MA, Ortwine DF, Franke Y, Cohen CJ, Hackos DH, Koth CM, Payandeh J.

Science. 2015 Dec 18;350(6267):aac5464. doi: 10.1126/science.aac5464.

PMID:
26680203
34.

In-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking Applications.

Betzer O, Meir R, Dreifuss T, Shamalov K, Motiei M, Shwartz A, Baranes K, Cohen CJ, Shraga-Heled N, Ofir R, Yadid G, Popovtzer R.

Sci Rep. 2015 Oct 28;5:15400. doi: 10.1038/srep15400.

35.

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.

Wilkins EL, Cohen CJ, Trottier B, Esser S, Smith DE, Haas B, Brinson C, Garner W, Chuck S, Thorpe D, De-Oertel S.

AIDS Care. 2016;28(3):401-8. doi: 10.1080/09540121.2015.1096890. Epub 2015 Oct 21.

PMID:
26489045
36.

The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression.

Vecellio M, Roberts AR, Cohen CJ, Cortes A, Knight JC, Bowness P, Wordsworth BP.

Ann Rheum Dis. 2016 Aug;75(8):1534-40. doi: 10.1136/annrheumdis-2015-207490. Epub 2015 Oct 9.

37.

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Clin Invest. 2015 Oct 1;125(10):3981-91. doi: 10.1172/JCI82416. Epub 2015 Sep 21.

38.

Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T-Cells in Vivo with Gold Nanoparticles and CT Imaging.

Meir R, Shamalov K, Betzer O, Motiei M, Horovitz-Fried M, Yehuda R, Popovtzer A, Popovtzer R, Cohen CJ.

ACS Nano. 2015 Jun 23;9(6):6363-72. doi: 10.1021/acsnano.5b01939. Epub 2015 Jun 11.

PMID:
26039633
39.

An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.

Tal Y, Yaakobi S, Horovitz-Fried M, Safyon E, Rosental B, Porgador A, Cohen CJ.

Oncotarget. 2014 Nov 15;5(21):10949-58.

40.

Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010.

Sun S, Cohen CJ, Dehnhardt CM.

Pharm Pat Anal. 2014 Sep;3(5):509-21. doi: 10.4155/ppa.14.39. Review. Erratum in: Pharm Pat Anal. 2014;3(6):640.

PMID:
25374320
41.

The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.

Sun S, Jia Q, Zenova AY, Chafeev M, Zhang Z, Lin S, Kwan R, Grimwood ME, Chowdhury S, Young C, Cohen CJ, Oballa RM.

Bioorg Med Chem Lett. 2014 Sep 15;24(18):4397-4401. doi: 10.1016/j.bmcl.2014.08.017. Epub 2014 Aug 14.

PMID:
25176194
42.

High-risk case identification for use in comprehensive complex care management.

Cohen CJ, Flaks-Manov N, Low M, Balicer RD, Shadmi E.

Popul Health Manag. 2015 Feb;18(1):15-22. doi: 10.1089/pop.2014.0011. Epub 2014 Jul 30.

PMID:
25075954
43.

Social values as an independent factor affecting end of life medical decision making.

Cohen CJ, Chen Y, Orbach H, Freier-Dror Y, Auslander G, Breuer GS.

Med Health Care Philos. 2015 Feb;18(1):71-80. doi: 10.1007/s11019-014-9581-x.

PMID:
24965073
44.

Reduction in myocardial infarction incidence: focus on socioeconomic disparities.

Reges O, Leibowitz M, Hoshen M, Rabi Y, Gluzman I, Cohen CJ, Balicer RD.

Int J Cardiol. 2014 Jul 1;174(3):773-4. doi: 10.1016/j.ijcard.2014.04.073. Epub 2014 Apr 15. No abstract available.

PMID:
24794958
45.
46.

Letter to the editor.

Goldberg YP, Cohen CJ, Namdari R, Price N, Cadieux JA, Young C, Sherrington R, Pimstone SN.

Pain. 2014 Apr;155(4):837-8. doi: 10.1016/j.pain.2014.01.003. Epub 2014 Jan 13. No abstract available.

PMID:
24434731
47.

Pneumococcal vaccine targeting strategy for older adults: customized risk profiling.

Balicer RD, Cohen CJ, Leibowitz M, Feldman BS, Brufman I, Roberts C, Hoshen M.

Vaccine. 2014 Feb 12;32(8):990-5. doi: 10.1016/j.vaccine.2013.12.020. Epub 2013 Dec 31.

PMID:
24384054
48.

Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.

Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ.

J Immunol. 2013 Oct 15;191(8):4121-9. doi: 10.4049/jimmunol.1203085. Epub 2013 Sep 11.

49.
50.

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.

HIV Clin Trials. 2013 May-Jun;14(3):81-91. doi: 10.1310/hct1403-81.

PMID:
23835510

Supplemental Content

Loading ...
Support Center